HCM
ABUS icon

Highlander Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Highlander Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-2,000
Closed -$15.9K – 845
2013
Q4 		$15.9K Hold
2,000
– – 0.02% 561
2013
Q3 		$13.9K Buy
+2,000
New +$11K 0.01% 595

Other funds holding ABUS

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
BIM
Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return
SCM
Sigma Capital Management Stamford, Connecticut $1.95B AUM 42.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Highlander Capital Management's ABUS Position: Q1 2014 in Review

Highlander Capital Management sold out of Arbutus Biopharma (ABUS) in Q1 2014, closing a stake of 2,000 shares — an estimated $15.9K sold.

Highlander Capital Management first reported a position in ABUS in Q3 2013 and held it in 2 quarters. The position peaked at $15.9K in Q4 2013. 50 funds tracked by Wall St. Rank hold ABUS as of Q1 2014.

  • Highlander Capital Management reported no remaining Arbutus Biopharma position as of Q1 2014 after selling out during the quarter.
  • Highlander Capital Management sold 2,000 Arbutus Biopharma shares in Q1 2014, an estimated $15.9K.
  • Highlander Capital Management first reported a position in Arbutus Biopharma in Q3 2013 and held it in 2 quarters.
  • Highlander Capital Management's Arbutus Biopharma position peaked at $15.9K in Q4 2013.
  • 50 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2014.

Based on Highlander Capital Management's 13F filing for Q1 2014, filed 8 May 2014.